Six SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin and tofogliflozin) have been available for the treatment of type 2 diabetes for ~5 years in Japan. Here, SLC5A2 is linked to type 2 diabetes mellitus.